No Data
Three clinical studies of Ascentage Pharma's Bcl-2 inhibitor APG-2575 were selected for presentation at the 2024 ASH conference, including one oral presentation!
Rockville City, Maryland, usa and Suzhou, china, November 6, 2024 / PRNewswire / - Ascentage Pharma (6855.HK), a leading biomedical company dedicated to developing innovative drugs in fields such as oncology, announced today that its key product APG-2575 (Lisaftoclax) has a total of 3 clinical advancements selected for the 66th American Society of Hematology (ASH) annual meeting, including one oral presentation. This marks the third consecutive year that this product's clinical advancements have been selected for the ASH annual meeting.
Express News | Ash 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report
【2024 ASH】Seventh consecutive championship! Natulek selected for multiple research projects for the seventh time, with one receiving an oral presentation.
Rockville, Maryland in the USA and Suzhou, China, November 6, 2024 / PRNewswire / -- Ascletis Pharma (6855.HK), a leading biomedical company dedicated to developing innovative drugs in fields like oncology, announced today that its original Class 1 new drug, Orelabatinib (trade name: Nalitinib), has multiple clinical advancements selected for the 66th Annual Meeting of the American Society of Hematology (ASH), with one receiving an oral presentation. This marks the seventh consecutive year of clinical advancements for this product being selected for oral presentations at the ASH conference.
CICC: Upgraded Aier Ophthalmology-B(06855) target price to 55 Hong Kong dollars, maintaining 'Outperform Industry' rating.
Recently, the company announced that the company's original class 1 new drug, FAK/ALK/ROS1 triple tyrosine kinase inhibitor (TKI) APG-2449, has been approved by the National Medical Products Administration, and will conduct two Phase III clinical studies for second-generation ALK TKI resistant or intolerant non-small cell lung cancer (NSCLC) or first-line ALK-positive advanced NSCLC.
HK Stock Market News | ASB Medicine-B (06855) surged over 4% again. APG-2449 approved for Phase III clinical trial, expected to enter a new stage of listing in the US.
A-Share Medicine-B (06855) rose over 4% again, reaching a high of HK$46.45, a three-year high. As of the time of writing, it's up 4.62%, at HK$46.45, with a turnover of HK$73.8857 million.
Would Ascentage Pharma Group International (HKG:6855) Be Better Off With Less Debt?
No Data
No Data
